Patients receiving commercial CAR-T therapy for their clinical care are invited to provide 5 blood draws at the time blood is drawn for their clinical care. The samples will be used to help develop a new technology for detecting CAR-T cells in the blood.
CAR-T detection by IVFC
CAR-T detection by label-free invitro flow cytometry
Lymphoma
All genders
18+
Recruiting now
Overview
Principal Investigator: Andreas Klein, MD
Contact Us
Andreas Klein, MD
Study details
Inclusion Criteria
- Scheduled to receive commercial CAR-T therapy targeting CD19
Study Requirements
Study participation will consist of 5 blood draws over the course of 4 weeks, totaling 40 mL (5 Tablespoons). Medical records related to CAR-T infusion will be reviewed for 3 months.